Alcon Inc. Ordinary Shares (ALC)

A second day of selling pressure hit technology stocks tied to the AI theme on Wednesday, as sentiment cooled after an MIT report questioned the broad profitability of the new technology.

Alcon cut its 2025 outlook citing higher tariffs, with Q2 sales missing estimates. Earnings topped forecasts, led by strong vision care demand.

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally.

Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?

Alcon will acquire STAAR Surgical for $1.5 billion to expand surgical vision correction options for high myopia, including EVO ICL lenses.

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Several stocks ranging from mega-cap to small-cap just announced notable increases to their dividends. One of these names is among the three largest stocks in the software industry.

Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract surgery.